Adaptimmune Therapeutics PLC (ADAP) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ADAP currently has 1.54B outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 1.94% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Oct 28, 2025 |
POS AM filing: This POS AM filing from 2025-10-28 relates to securities registered but unsold or unissued from a previous S-3 filing (File No. 333-286639) on 2025-04-18, covering an indeterminate number of American Depositary Shares, Warrants, Units, or any combination, with an aggregate initial public offering price not to exceed $400 million. |
1.5B | 0 |
| May 13, 2025 |
10-Q filing | 1542.2M shares outstanding |
1.5B | 1.3B |
| Apr 18, 2025 |
S-3 filing: The company is filing an S-3 to offer a combination of securities, including American Depositary Shares, up to an aggregate amount of $400,000,000 and ADSs having an aggregate offering price of up to $200,000,000 through an at-the-market offering. |
1.5B | 1.4B |
| Mar 24, 2025 |
10-K filing | 1513.8M shares outstanding |
1.5B | 0 |
| Nov 13, 2024 |
10-Q filing | 1534.6M shares outstanding |
1.5B | 0 |
| Aug 12, 2024 |
10-Q filing | 1533.5M shares outstanding |
1.5B | 0 |
| May 15, 2024 |
10-Q filing | 1451.2M shares outstanding |
1.5B | 0 |
| Mar 06, 2024 |
10-K filing | 1363.0M shares outstanding |
1.4B | 0 |
| Nov 08, 2023 |
10-Q filing | 1357.8M shares outstanding |
1.4B | 0 |
| Aug 09, 2023 |
10-Q filing | 1351.8M shares outstanding |
1.4B | 0 |
| May 12, 2023 |
10-Q filing | 991.3M shares outstanding |
990M | 140M |
| Mar 06, 2023 |
10-K filing | 967.2M shares outstanding |
970M | 170M |
| Nov 08, 2022 |
10-Q filing | 980.8M shares outstanding |
980M | 150M |
| Aug 04, 2022 |
10-Q filing | 962.8M shares outstanding |
960M | 170M |
| May 09, 2022 |
10-Q filing | 940.0M shares outstanding |
940M | 190M |
| Apr 21, 2022 |
S-3/A filing: The company may offer any combination of securities described in the prospectus, up to an aggregate amount of $400,000,000, including American Depositary Shares representing Ordinary Shares with an aggregate offering price of up to $200,000,000 through an at-the-market offering. |
930M | 200M |
| Apr 08, 2022 |
S-3 filing: The company intends to offer ADSs, through Cowen, acting as sales agent, for an aggregate offering price of up to $200,000,000 in an at the market offering. The company intends to use the net proceeds for general corporate purposes. |
930M | 0 |
| Mar 14, 2022 |
10-K filing | 934.8M shares outstanding |
930M | 0 |
| Nov 04, 2021 |
10-Q filing | 937.0M shares outstanding |
940M | 0 |
| Aug 09, 2021 |
10-Q filing | 936.2M shares outstanding |
940M | 0 |
| May 06, 2021 |
10-Q filing | 932.8M shares outstanding |
930M | 0 |
| Feb 25, 2021 |
10-K filing | 928.8M shares outstanding |
930M | 0 |
| Nov 05, 2020 |
10-Q filing | 928.5M shares outstanding |
930M | 0 |
| Aug 06, 2020 |
10-Q filing | 927.7M shares outstanding |
930M | 0 |
| Jun 02, 2020 |
8-K filing: Adaptimmune Therapeutics plc entered into an underwriting agreement to issue and sell 20,500,000 American Depositary Shares (ADSs) at a public offering price of $11.00 per ADS, with the offering expected to close on June 4, 2020. ($225.5M proceeds) |
780M | 0 |
| May 14, 2020 |
10-Q filing | 780.5M shares outstanding |
780M | 0 |
| Feb 27, 2020 |
10-K filing | 631.0M shares outstanding |
630M | 0 |
| Feb 07, 2020 |
8-K filing: Adaptimmune Therapeutics plc announced that the underwriters of its previously announced public offering exercised their option to purchase an additional 3,150,000 ADSs at $4.00 per ADS, which closed on February 7, 2020. ($12.6M proceeds) |
N/A | 0 |
| Jan 22, 2020 |
8-K filing: Adaptimmune Therapeutics plc entered into an underwriting agreement to issue and sell 21,000,000 American Depositary Shares (ADSs) at a price of $4.00 per ADS, with the offering expected to close on January 24, 2020. ($84.0M proceeds) |
N/A | 0 |